Skip to main content Skip to search Skip to search

Medical Oncology

EBNA1 and Epstein-Barr Virus Associated Tumours

by (author) Lori Frappier

Publisher
Springer/Sci-Tech/Trade
Initial publish date
Apr 2013
Category
Oncology, Microbiology
  • Paperback / softback

    ISBN
    9781461468851
    Publish Date
    Apr 2013
    List Price
    $80.5

Classroom Resources

Where to buy it

Description

This SpringerBrief is comprehensive account of the functions and effects of the Epstein-Barr virus (EBV) EBNA1 protein that relate to EBV-associated cancers and evidence for EBNA1 contributions to these cancers. EBNA1 was the first EBV protein detected and the most critical for EBV latent infection. EBNA1 fulfills multiple functions at EBV genomes which have been described in many (sometimes confusing) reports over the last 28 years. While these were initially thought to be the only roles of EBNA1, many reports in recent years have shown that EBNA1 also directly affects cellular processes in ways that would be expected to contribute to oncogenesis. However, the degree to which EBNA1 promotes cell survival and oncogenesis in various types of human tumours is not entirely clear and a matter of debate. This book offers a current synopsis of EBNA1 functions in EBV latency, including functions in DNA replication, mitotic segregation and transcription. Mechanisms of these EBNA1 functions is also discussed as well as implications for tumourigenesis. In addition, the cellular effects of EBNA1 will be reviewed, including how EBNA1 manipulates specific cellular proteins and relationships to EBV-associated lymphomas and carcinomas.

About the author

Contributor Notes

Lori Dawn Frappier, Ph.D., is a Professor in the Department of Molecular Genetics at the University of Toronto and a Canada Research Chair in Molecular Virology. She specializes in researching mechanisms by which viruses persist and induce cancer in human cells. According to Scopus, Dr. Frappier has an H-index of 25; she has published over 80 papers and has been cited over 2700 times. Please see attached short CV for additional details.